Integra Lifesciences Holdings Corporation · NASDAQ:IART
Integra Lifesciences — J.P. Morgan Healthcare Conference 2026
14 slides from Integra Lifesciences's conference presentation, January 2026
Slide 1: Integra LifeSciences – J.P. Morgan Healthcare Conference
Integra LifeSciences J.P. Morgan Healthcare Conference January 2026
Slide 2: Forward-looking statements
Forward-looking statements Slide 2
Slide 3: A global medtech leader dedicated to restoring lives
A global medtech leader dedicated to restoring lives Demonstrated leadership in $9B global market Extensive portfolio of best-in-class products $1.6B 62.8% LTM reported LTM adjusted revenue gross margin Executing strategic transformation Strengthening operational foundation 19% LTM adjusted $89M LTM
Slide 4: Leadership in large global markets
Leadership in large global markets Highly differentiated products trusted by healthcare professionals and systems Codman Specialty Surgical (CSS) Global Opportunity Tissue Technologies (TT) $1.1B1 $0.5B1 Neurosurgery & ENT $3.4B Mid-single-digit growth Complex Wound Neurosurgery Reconstruction TAM $
Slide 5: Our right to win in attractive core markets
Our right to win in attractive core markets Addressing key market trends with differentiated capabilities Healthcare market trends Opportunities Growing adoption in international of new technologies markets Changing Shifting point-of- reimbursement Disease states driven by Geopolitical care to alter
Slide 6: Our vision
Our vision Advancing transformational care, delivering impactful innovation, and enriching life moments. Slide 6
Slide 7: Delivering our vision
Delivering our vision Solidify market leadership, build a culture of quality and execution excellence, drive company performance Integra’s strategic imperatives Deliver Drive supply Accelerate Ignite best-in-class chain reliability growth innovation quality Transform to excel and consistently delive
Slide 8: Horizon 1: Building a sustainable foundation
Horizon 1: Building a sustainable foundation A systemic, foundational transformation to drive consistent and reliable performance Focus area Improved outcomes • Delivery on warning letter actions Quality Quality management system • Favorable regulatory audit outcomes • Product quality consistency •
Slide 9: Horizon 2: Delivering accelerated growth
Horizon 2: Delivering accelerated growth Investing to enable innovation and drivers of growth • New technologies and Organic and inorganic innovation market segments • Expanding Neurosurgery and New product introductions ENT category leadership • Advance skin substitutes and Clinical evidence genera
Slide 10: Uniquely positioned to capture opportunities from outpatient skin substitute reimbursement
Uniquely positioned to capture opportunities from outpatient skin substitute reimbursement Reimbursement rate changes are foundational Integra's position aligned with potential in leveling access across sites of care Medicare changes under consideration 2025 and prior 2026 ~$1,3001 $127 2 >250 ~20 A
Slide 11: Integra: Restoring lives
Integra: Restoring lives Advancing transformational care, delivering impactful innovation, and enriching life moments 1 Favorable sector dynamics • • Aging population Increase in procedural volumes 2 High value, high demand portfolio • Strong brand equity and product differentiation • Adoption of ne
Slide 12: Appendix
Appendix Slide 12
Slide 13: Trailing twelve month adjusted EBITDA and adjusted gross margin reconciliation
Appendix Trailing twelve month adjusted EBITDA and adjusted gross margin reconciliation (In millions) TTM Q3 2025 GAAP Net Income (495.3) Depreciation 43.6 Intangible asset amortization 106.7 Goodwill impairment charge 511.4 Other (income), net 1.5 Interest expense, net 61.3 Income tax expense/(bene
Slide 14: Non-GAAP financial disclosure
Non-GAAP financial disclosure In addition to our GAAP results, we provide certain financial measures and guidance which are considered “non-GAAP” under applicable SEC rules and regulations, including adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”) margin and adjust
Integra LifeSciences — J.P. Morgan Healthcare Conference 2026 on 6ix